Tay-Sachs Disease Incidence and Carrier Rates by Population

Tay-Sachs disease (TSD) incidence varies dramatically by ancestry due to founder mutations and genetic drift.

Carrier Frequencies & Disease Incidence

PopulationCarrier FrequencyDisease Incidence (Carrier Couple)
Ashkenazi Jewish1 in 27–30~1 in 3,600
French Canadian (SE Quebec)1 in 15–20~1 in 900–1,600
Cajun (Louisiana)1 in 30–40~1 in 3,600–6,400
Irish American1 in 50~1 in 10,000
General (non-high-risk)1 in 250–300~1 in 250,000–360,000

Notes on Estimates

  • Incidence assumes random mating within population; actual rates depend on screening uptake.
  • Ashkenazi screening (since 1970s) reduced births >90%; current incidence in screened communities near zero.
  • French Canadian rate elevated due to distinct founder mutation (7.6 kb deletion).
  • Pseudodeficiency allele (R247W/R249W) frequency ~1/50 in general pop; causes false enzyme-screen positives.

Screening Recommendations (ACMG/NSGC)

  • Targeted: Ashkenazi Jewish, French Canadian, Cajun ancestry → HEXA panel + enzyme.
  • Pan-ethnic: Offered to all pregnant/planning couples (expanded panels include TSD).
  • Timing: Preconception ideal; early prenatal if not done prior.

Clinical Utility

  • Identifies carrier couples → reproductive options (prenatal Dx, PGT-M, donor gametes).
  • Does not benefit fetus directly (no in utero treatment).
  • Cost-effective in high-prevalence groups; debated for general population.

Accurate carrier detection requires combined enzyme + molecular testing to avoid pseudodeficiency confusion.

Baby Health - Related Articles